People

Kiutra lists Ulrich Kruse in its Board and advisors directory as its TRUMPF Venture representative. The directory does not specify a separate director or adviser title.

Kiutra lists Christian Ziach in its Board and advisors directory as its High-Tech Gründerfonds representative. The directory does not specify a separate director or adviser title.

Mark Jacobstein serves Luminopia as Board Member. The company also identifies him as an executive business advisor at Immunai and formerly CUEO at Guardant Health.

Scientist and investor who co-founded Iris Medicine and Kelonia Therapeutics; previously worked at Venrock.

Senior R&D adviser at Ovid Therapeutics, also described as executive R&D adviser in its biography and July 2026 announcement. A physician with pharmaceutical development experience across neurology and psychiatry; prior leadership includes Passage Bio, Acadia, Shire, Elan and Wyeth. Ovid’s biography confirms continued executive work at Delix Therapeutics.

Novoron Bioscience executive chairman and director, and Bright Minds Biosciences non-executive director; physician with neurological drug development experience at ACADIA, Proteostasis and Lumos.

Healthcare venture investor and venture partner at Think.Health, also listed by Angelini Ventures as a principal focused on digital health.

Scientific and clinical adviser to Ovid Therapeutics. An NYU neurologist and epilepsy clinical trial researcher who also serves as chief scientific officer of the Epilepsy Foundation. Her existing advisory roles at Bloom Science, Neumirna, Axonis and Montara are preserved.

Melanie Leitner is chief scientific officer and a partner of ALS Investment Fund. The fund’s December 2025 announcement describes her as a neuroscientist with more than 25 years of translational research and development experience, including Biogen and Prize4Life. Her work concerns cross-sector ALS research and development.

Apollo Health Ventures current own career biography: Alexandra has dedicated her life to the improvement of health and medicine and co-founded Apollo with Nils and Ole in 2017. She is a Venture Partner at Apollo. She is deeply involved in Apollo’s Venture Lab where she focused on identifying company building opportunities through her close ties with global leading research institutes and researchers in the aging sector Alexandra worked in BCG’s healthcare practice specializing in biopharma strategy, market assessment and asset diligence She did her PhD studies at Harvard Medical School focusing on molecular mechanisms that contribute to cellular aging and is a trained pharmacist Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Felix von Coerper is a managing partner and founder of ALS Investment Fund. The December 2025 announcement describes more than 25 years as an entrepreneur and life-sciences investor and identifies his Amylyx board appointment as former. His work concerns financing therapies for ALS and related neurodegenerative diseases.

Co-founder and chief scientific officer of Bexson Biomedical; psychiatrist working in ketamine-assisted psychotherapy, applied genetics and functional nutrient science.

Physician-scientist and life sciences investor with a background in neurology and Alzheimer’s biomarkers; co-founder of EQT Life Sciences’ Dementia Fund.

Jefferson Life Sciences strategic adviser and biotechnology partnerships executive. Previously led external innovation at Novo Nordisk; also serves on Aerska's board.

George Church is Harvard’s Robert Winthrop Professor of Genetics and a researcher in genomic reading, writing and synthetic biology. Lila named him chief scientist in its 2025 launch-era statement. He is absent from Lila’s current published leadership roster, so continued company employment is unverified. Existing scientific advisory affiliations are preserved; a company role does not establish a personal investment.

Medical executive and biotech entrepreneur who founded Gentium and has held multiple life-sciences board roles. IAG publishes Laura Iris Ferro as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Presidente in Bio4Dreams. Life Science Manager e imprenditore nel settore Farmaceutico e biotech con esperienze internazionali. Laura è Specializzata nel settore Psichiatrico e clinico farmacologico. Attualmente Laura è Presidente di Bio4Dreams. Inoltre Laura è anche advisor per Panakes Partners, fondo di venture capital nel settore LifeScience. Champion:

Raffaella Basile is identified in the manager-published team roster as Team Assistant. Additional career history is not verified from available primary sources.

Francesco Zelano is listed as Senior Investment Manager in an undated cached Indaco manager roster. Newer indexed versions omit this name, so current affiliation is unconfirmed; original role and identity are preserved.

Elisa Beltrami is listed as Senior Investment Manager in an undated cached Indaco manager roster. Newer indexed team versions omit this name, so current employment is unconfirmed. Elisa is not assumed to be Elena Beltrami, a differently named BIO adviser listed elsewhere.

Senior Investment Manager at Indaco. Previously worked at Microsoft supporting financial-services digital transformation, advised the Italian Institute of Technology and founded We Start Italy after consulting at Accenture. Holds telecommunications-engineering degrees and a Bocconi MBA.

Partner and investment-committee member of Indaco BIO sinceSeptember2022. Previously worked in drug discovery at Elan and Bioalvo, established and managed Hovione Capital and led business operations at Nanoform. Trained in microbiology/genetics inLisbon, biochemistry/pharmacy inMunich and business administration. Own profile heading misspells Gonzalo while biography and roster consistently use Goncalo.

Partner and investment-committee member of Indaco BIO. Has biology, oncology, microbiology and business training, with a drug-development career including Intercept Pharmaceuticals, iDNA, Yaqrit and Zcube. Own biography also reports academic affiliations at UCL and Milano Bicocca.

Ilaria Ceccovecchi is identified in the manager-published team roster as Team Assistant. Additional career history is not verified from available primary sources.

Finance and Administration Assistant at Indaco. Previously worked in financial-services consulting atDeloitte/EY Luxembourg, fund administration atMC Square and corporate finance atFinsa. Holds LUISS management/corporate-finance and Bocconi strategy/entrepreneurship qualifications.

Head of Legal and HR at Indaco, responsible for corporate-secretarial, legal, organisational and personnel work. Previously led legal/compliance work atPensPlan InvestSGR and has lectured on financial regulation. Holds a law degree fromGenoa.

Chief Financial Officer at Indaco. Previously CFO at Azimut LiberaImpresa and worked in administration and finance atOpera and CapeNatixis after financial-services auditing atDeloitte. Holds a Bocconi financial-markets degree and experience overseeing manager/fund accounts and regulatory relationships.

Venture Partner at Indaco. Previously led healthcare seed funds Eporgen Venture and Filarete Investimenti, worked in technology strategy consulting and helped build WishDays as COO before its2016 sale. Trained in economics and business atTorino and ESCP-EAP.

Venture Partner at Indaco with industrial-engineering and management training from Politecnico diMilano and Bocconi. Career includes enterprise telecommunications, Vodafone, DeutscheBank, RAI, Qualcomm and payments. Own biography describes seed-stage angel investing and corporate-innovation advisory work; no personal cash investments are inferred.

Investment Analyst at Indaco, following an internship beginningMarch2025 and a permanent analyst appointment inSeptember2025. Holds a Milano-Bicocca economics degree and LIUC private-equity/finance training; own biography lists further postgraduate studies expected to finishOctober2026.

Investment Analyst at Indaco with earlier experience in fundraising and financial control at a space-technology startup and at PwC. Holds business-administration degrees from Luiss and Brescia, with study exchanges inChina and theNetherlands.

Indaco co-founder and Investment Director with an engineering and venture-investment background. Previously researched embedded and wireless systems at Berkeley, worked at McKinsey and joined IMI Fondi Chiusi in2009. Holds engineering degrees from Padua and Berkeley, including a PhD.

Indaco co-founder, board member and Investment Director. Serves investment committees for Indaco VenturesI and the Atlante funds, following more than twenty years in venture capital and private equity. Holds a Bocconi business degree and is a chartered accountant.

IAG publishes Elizabeth Robinson as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Imprenditrice e venture capitalist settore BioTech. Life Science Laureata negli USA ma residente in Italia da piu di 30 anni, Elizabeth è una venture capital con diversi anni di esperienza nel settore life science. Elizabeth ama andare in bicicletta e il trekking. Champion: Elizabeth Robinson is identified in the manager-published team roster as Co-founder and Vice Chairman. Additional career history is not verified from available primary sources.

Co-founded Indaco in2016 and has led it as Managing Director. Previously led venture-capital activity at Intesa Sanpaolo, helping launch the Atlante funds after earlier private-equity work. Holds a Bocconi business degree and qualified as a chartered accountant in1995.